institutional_protocol: DIABETES_T2_MGMT_002
Title: Type 2 Diabetes Mellitus Glycemic Control
Version: 2024.2

1. TARGETS
- General HbA1c target: < 7.0%.
- Pre-prandial glucose: 80-130 mg/dL.
- Post-prandial glucose (1-2h after meal): < 180 mg/dL.

2. FIRST-LINE THERAPY
- Metformin is the preferred initial pharmacologic agent for the treatment of type 2 diabetes.
- Initial dose: 500mg daily with meals. Titrate to 1000mg twice daily as tolerated.

3. SECOND-LINE AGENTS (Add-on if HbA1c > 7.0% after 3 months)
- GLP-1 Receptor Agonists (e.g., Semaglutide) if ASCVD or CKD present.
- SGLT2 Inhibitors (e.g., Empagliflozin) if heart failure or CKD present.
- DPP-4 Inhibitors or Sulfonylureas (lower cost options).

4. SAFETY & MONITORING
- Metformin: Monitor renal function (eGFR). Contraindicated if eGFR < 30 mL/min/1.73mÂ².
- Sulfonylureas (e.g., Glipizide): High risk of hypoglycemia.
